Novartis India has launched 'Pluvicto', the first regulatory authority-approved radioligand therapy (RLT) in India for advanced prostate cancer.
This precision medicine is indicated for patients with Prostate-Specific Membrane Antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).